Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00521222 · ClinicalTrials.gov registry record · NA
Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT00521222 is a NA study that has completed, run by Columbia University. The registered enrollment target is 90 participants.
The verdict
NCT00521222, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
The investigators are conducting a study of asthma patients who use fluticasone with salmeterol (Advair) or any other combination of an inhaled corticosteroid (ICS) and a long acting beta agonist (LABA) to manage their asthma symptoms. Participants begin the study by continuing to use fluticasone with salmeterol or substituting fluticasone with salmeterol for their current ICS/LABA medication at their regular dose or the comparable dose(all study medications are provided) for a six-week period. Patients are then separated into 2 groups: one group is asked to use fluticasone (Flovent), the other to use fluticasone with salmeterol , twice daily over a 16-week period (patients will need to be seen monthly during this time). Neither study personnel nor patients will know which drug is being used. Patients are also asked to use a peak flow meter and record their daily results on a form, along with the number of puffs they use of their rescue inhaler each day. They also record any changes in asthma medications and information on any asthma episodes. The investigators hypothesize that there are certain patients with asthma who will do better when a long acting beta agonist is removed from their maintenance asthma medications.
Interventions
- DRUG Fluticasone with salmeterol
- DRUG Fluticasone HFA
- DRUG Ipratropium HFA
- DRUG Albuterol HFA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2007-06 |
| Est. Completion | 2010-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00521222
The ClinicalTrials.gov registry entry for NCT00521222 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Fluticasone with salmeterol is the first listed.
NCT00521222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00521222 about?
NCT00521222 is a clinical study titled "Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes". The investigators are conducting a study of asthma patients who use fluticasone with salmeterol (Advair) or any other combination of an inhaled corticosteroid (ICS) and a long acting beta agonist (LABA) to manage their asthma symptoms. Participants begin the study by continuing to use fluticasone w...
What is the current status of trial NCT00521222?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2007-06. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00521222?
The interventions under investigation include: Fluticasone with salmeterol (DRUG), Fluticasone HFA (DRUG), Ipratropium HFA (DRUG), Albuterol HFA (DRUG).
Who is sponsoring clinical trial NCT00521222?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.